Doctors believe they are closer to a treatment for multiple sclerosis after discovering a drug that repairs the coatings around nerves that are damaged by the disease.

A clinical trial of the cancer drug bexarotene showed that it repaired the protective myelin sheaths that MS destroys. The loss of myelin causes a range of neurological problems including balance, vision and muscle disorders, and ultimately, disability.

While bexarotene cannot be used as a treatment, because the side-effects are too serious, doctors behind the trial said the results showed remyelination was possible in humans, suggesting other drugs or drug combinations will halt MS.

Its disappointing that this is not the drug well use, but its exciting that repair is achievable and it gives us great hope for another trial we hope to start this year, said Prof Alasdair Coles, who led the research at the University of Cambridge.

MS arises when the immune system mistakenly attacks the fatty myelin coating that wraps around nerves in the brain and spinal cord. Without the lipid-rich substance, signals travel more slowly along nerves, are disrupted, or fail to get through at all. About 100,000 people in the UK live with the condition.

Funded by the MS Society, bexarotene was assessed in a phase 2a trial that used brain scans to monitor changes to damaged neurons in patients with relapsing MS. This is an early stage of the condition that precedes secondary progressive disease, where neurons die off and cause permanent disability.

The drug had some serious side-effects, from thyroid disease to raised levels of fats in the blood, which can lead to dangerous inflammation of the pancreas. But brain scans revealed that neurons had regrown their myelin sheaths, a finding confirmed by tests that showed signals sent from the retina to the visual cortex at the back of the brain had quickened. That can only be achieved through remyelination, said Coles.

Details of the work were presented on Friday at MSVirtual2020, a joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis and its Americas counterpart.

While bexarotene will not go into phase 3 trials for MS, the finding that the nervous system can be stimulated to resheath damaged neurons has given scientists fresh hopes for another trial they hope to launch later this year. That trial will monitor the effects of the diabetes drug metformin along with clemastine, an antihistamine, a combination that Prof Robin Franklin at the Wellcome-MRC Cambridge Stem Cell Institute showed last year could drive remyelination in animals.

Metformin seems to work by rejuvenating stem cells in the central nervous system, which then go on to become myelin-producing cells called oligodendrocytes. These churn out fresh myelin to replace that destroyed by MS. The researchers hope the drug combination will at least slow the progression of the disease, but there is a chance it will prevent further damage to neurons completely.

The results of this trial give us confidence that medicines that promote myelin regeneration will have a real impact on the treatment of MS, and we look forward to the outcome of future trials with increased optimism, said Franklin.

Dr Emma Gray, at the MS Society, said: Finding treatments to stop MS progression is our number one priority, and to do that we need ways to protect nerves from damage and repair lost myelin. This new research is a major milestone in our plan to stop MS and were incredibly excited about the potential its shown for future studies.

Continue reading here:
MS treatment a step closer after drug shown to repair nerve coating - The Guardian

Answers Tatyana Donskikh, head of the clinical diagnostic department, including a day hospital, neurologist of the Federal Center for Medical Sciences of the Federal Medical and Biological Agency of Russia:

Despite all the efforts of modern medicine, no remedy has yet been found that can cure dementia. But it is possible to slow down the development of the disease! And these chances must be used.

Modern treatment is carried out mainly in two directions:

1. Drug therapy.

2. Optimal care that supports mental initiative and a sense of security.

The drugs available to people with dementia today can be divided into three groups:

This group includes a drug used to treat dementia of all severity. Since the binding sites of glutamate are present only in the brain and spinal cord, the agent is well tolerated and has practically no contraindications for administration. This is very important for elderly patients who often have many concomitant diseases.

This group of drugs includes a number of drugs. They prevent the breakdown of acetylcholine already formed in the brain. They are prescribed for mild to moderate severity of the disease. Since acetylcholine is often found outside the brain, acetylcholinesterase inhibitors can cause a number of side effects.

Treatment is carried out for a long time, first as monotherapy, then in combination.

Non-drug approaches to treatment are important, in particular, psychological support for patients and their relatives, neuropsychological training, music therapy, phototherapy, art therapy, aromatherapy and other methods of additional sensory stimulation, therapeutic gymnastics, etc.

Since the prevalence of Alzheimers disease is expected to grow rapidly in the world and the existing therapeutic approaches are rather modest, the search for new forms of action and methods of treatment continues constantly. There are many of these directions. These include, for example, the development of new neuroprotective drugs, neuroreparation technologies using stem cells. Particular hopes were pinned on immunological approaches associated with the use of amyloid vaccines and immunoglobulins in attempts to remove -amyloid from the brain. Unfortunately, clinical trials of amyloid vaccines have shown an unacceptably high risk of developing encephalitis or leukoencephalopathy.

The maximum benefit from any effective remedy is possible only when applied at an early, pre-demented stage of the pathological process. Therefore, it is so important to develop approaches to the earliest possible diagnosis of Alzheimers disease.

There are contraindications, you need to consult a doctor

Read more from the original source:
What treatments can prolong the life of someone with Alzheimer's? - Pledge Times

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 09/23/2020 -- Transparency Market Research (TMR) has published a new report on the global cell separation technology market for the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~ US$ 5 Bn in 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such as stem cell research and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach 73%, and in developing counties, 70% deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimer's, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion by 2100.

Request for Analysis of COVID19 Impact on Cell Separation Technology Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1925

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development of microfluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration (CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDA's clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

For more information on this press release visit: http://www.sbwire.com/press-releases/cell-separation-technology-mar/release-1305278.htm

Read more from the original source:
Cell Separation Technology Market: Productive Partnerships in Microfluidics Likely to Boost the Market Growth - Press Release - Digital Journal

MINNEAPOLIS, Sept. 24, 2020 /PRNewswire/ --Today, Senator Jack Reed (D-RI) introduced the TRANSPLANT Act (S. 4762), which will provide for the timely reauthorization of the C.W. Bill Young Transplantation Program (Program). The National Marrow Donor Program(NMDP)/Be The Match applauds the leadership of Senator Reed and urges Congress to act quickly to reauthorize the Program, which expires on September 30th.

"We appreciate the leadership of the bill's sponsor Sen. Jack Reed (D-RI), and the bipartisan support of the bill's lead cosponsors Sens. Richard Burr (R-NC), Tina Smith (D-MN), and Tim Scott (R-SC)," said NMDP/Be The Match Chief Policy Officer Brian Lindberg.

The Program provides access to live-saving bone marrow, peripheral blood stem cell (PBSC) and cord blood transplants to those living with one of the more than 70 blood cancers or blood disorders for which a transplant is the only curative option.

Since its inception in the mid-1980s, NMDP/Be The Match has been entrusted by Congress to operate the Program and has facilitated more than 100,000 life-saving transplants to give patients with otherwise fatal blood cancers or blood disorders a second chance at life.

The COVID-19 pandemic with increasingly restrictive travel bans, border closings, and the declining availability of scheduled commercial passenger aviation service on international and domestic routes - has created unprecedented obstacles for NMDP/ Be The Match in delivering life-saving cells to the patients who need them.

This new reality creates a web of increasingly complex challenges in facilitating the timely collection and delivery of bone marrow products to patients who are in the midst of treatment protocols or whose conditions have deteriorated to the point that a bone marrow transplant is the only course of treatment that will save their life.

"During the pandemic, we have been able to mitigate any disruption to our mission and complete more than 3,000 lifesaving therapies without missing a single delivery," continued Lindberg. "We have been able to do that, in large part, because of our designation in Federal law as the nation's bone marrow registry. Unfortunately, that designation will lapse with the expiration of our Federal authorization on September 30, 2020."

This designation has helped Be The Match to care for our patients during the pandemic by:

"Our ability to call upon our Federal partners in these extreme circumstances, and our standing in the eyes of foreign governments where we must operate, could be compromised after September 30th if our authorization expires and we are no longer technically designated as the Nation's registry," said Lindberg. "This could put at risk our ability to continue to ensure the timely delivery of life-saving cellular products to otherwise terminally ill patients here and throughout the world.

"Ensuring access to cellular therapy is critical for the patients we serve," continued Lindberg. "Congress must move immediately to reauthorize these programs to expand the number of adult volunteer donors and cord blood units on the national registry so that every American who needs a transplant can find a match."

About Be The MatchFor people with life-threatening blood cancerslike leukemia and lymphomaor other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. People can contribute to the cure as a member of the Be The Match Registry, financial contributor or volunteer. Be The Match provides patients and their families one-on-one support, education, and guidancebefore, during and after transplant.

Be The Match is operated by the National Marrow Donor Program (NMDP), a nonprofit organization that matches patients with donors, educates health care professionals and conducts research through its research program, CIBMTR (Center for International Blood and Marrow Transplant Research), so more lives can be saved. To learn more about the cure, visit BeTheMatch.org or call 1 (800) MARROW-2.

SOURCE Be The Match

https://bethematch.org

View post:
National Marrow Donor Program/Be The Match Urges Congress to Quickly Pass Reauthorization Bill to Protect Access to Life Saving Bone Marrow and Cord...

Latest Research Study on Stem Cell Therapy Market published by The Insight Partners, offers a detailed overview of the factors influencing the global business scope. The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Stem Cell Therapy market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries. Some of the key players profiled in the study are MEDIPOST, Pharmicell Co., Inc., RichSource, BioTime Inc. (Lineage Cell Therapeutics, Inc.), Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., Caladrius Biosciences, Inc., TiGenix NV, AlloSource, etc.

The stem cell therapy marketwas valued at US$ 1,534.55 million in 2019 and is expected to grow at a CAGR of 16.7% from 2020to 2027 to reach US$ 5,129.66 million by 2027.

Request Sample Copy of Stem Cell Therapy Market at: https://www.theinsightpartners.com/sample/TIPHE100000991/

Stem Cell Therapy Market In-Depth Analysis

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated. The global stem cell therapy market is driven by factors such asincreasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines. However, high cost related with stem cell therapy is likely to obstruct the growth of the stem cell therapymarket during the forecast period. The growing research and development activities in Asia Pacific region is expected to offer huge growth opportunity for stem cell therapy market.

End User Insights

Based on end user, the Stem Cell Therapy market is segmented into academic and research institutes, hospitals and specialty clinics. The academic and research institutes held the largest share of end user segment in the global market and is expected to grow at the fastest rate during the forecast period.

Key Benefits

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Stem Cell Therapy market. The researcher provides an extensive analysis of the Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Stem Cell Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Stem Cell Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Stem Cell Therapy market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Global Stem Cell Therapy Market By Type

Global Stem Cell Therapy Market By Treatment

Global Stem Cell Therapy Market ByApplication

Global Stem Cell Therapy Market By End User

Promising Regions & Countries Mentioned in TheStem Cell Therapy Market Report:

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPHE100000991/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Read more here:
Massive Growth Seen in Stem Cell Therapy Market 2020-2027 | In Depth Analysis with Top Key Players RichSource, Mesoblast Limited, TiGenix NV,...

Los Angeles, United State, The report titledGlobal Hematopoietic Stem Cell Transplantation (HSCT) Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Hematopoietic Stem Cell Transplantation (HSCT) market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Hematopoietic Stem Cell Transplantation (HSCT) market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Hematopoietic Stem Cell Transplantation (HSCT) market is carefully analyzed and researched about by the market analysts.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Top Key Players of the Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc Hematopoietic Stem Cell Transplantation (HSCT)

>>>Download Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528548/global-hematopoietic-stem-cell-transplantation-hsct-market

The Essential Content Covered in the Global Hematopoietic Stem Cell Transplantation (HSCT) Market Report :

Top Key Company Profiles.Main Business and Rival InformationSWOT Analysis and PESTEL AnalysisProduction, Sales, Revenue, Price and Gross MarginMarket Size And Growth RateCompany Market Share

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation By Product:, Allogeneic, Autologous Hematopoietic Stem Cell Transplantation (HSCT)

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation By Application: Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT), Cord Blood Transplant (CBT)

In terms of region, this research report covers almost all the major regions across the globe such asNorth America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. WhileHematopoietic Stem Cell Transplantation (HSCT) Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Hematopoietic Stem Cell Transplantation (HSCT) Market in South, America region is also expected to grow in near future.

Key questions answered in the report

*What will be the market size in terms of value and volume in the next five years?*Which segment is currently leading the market?*In which region will the market find its highest growth?*Which players will take the lead in the market?*What are the key drivers and restraints of the markets growth?

We provide detailed product mapping and analysis of various market scenarios. Our analysts are experts in providing in-depth analysis and breakdown of the business of key market leaders. We keep a close eye on recent developments and follow latest company news related to different players operating in the global Hematopoietic Stem Cell Transplantation (HSCT) market. This helps us to deeply analyze companies as well as the competitive landscape. Our vendor landscape analysis offers a complete study that will help you to stay on top of the competition.

Why to Buy this Report?

>>>Get Full Report in your inbox within 24 hours at USD(3900): https://www.qyresearch.com/settlement/pre/99cec1e27c598bf4f0d2c4a69d60697f,0,1,global-hematopoietic-stem-cell-transplantation-hsct-market

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Hematopoietic Stem Cell Transplantation (HSCT) Revenue1.4 Market by Type1.4.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size Growth Rate by Type: 2020 VS 20261.4.2 Allogeneic1.4.3 Autologous1.5 Market by Application1.5.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share by Application: 2020 VS 20261.5.2 Peripheral Blood Stem Cells Transplant (PBSCT)1.5.3 Bone Marrow Transplant (BMT)1.5.4 Cord Blood Transplant (CBT)1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Perspective (2015-2026)2.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Growth Trends by Regions2.2.1 Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Hematopoietic Stem Cell Transplantation (HSCT) Historic Market Share by Regions (2015-2020)2.2.3 Hematopoietic Stem Cell Transplantation (HSCT) Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Hematopoietic Stem Cell Transplantation (HSCT) Market Growth Strategy2.3.6 Primary Interviews with Key Hematopoietic Stem Cell Transplantation (HSCT) Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Hematopoietic Stem Cell Transplantation (HSCT) Players by Market Size3.1.1 Global Top Hematopoietic Stem Cell Transplantation (HSCT) Players by Revenue (2015-2020)3.1.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Revenue Market Share by Players (2015-2020)3.1.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Concentration Ratio3.2.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Hematopoietic Stem Cell Transplantation (HSCT) Revenue in 20193.3 Hematopoietic Stem Cell Transplantation (HSCT) Key Players Head office and Area Served3.4 Key Players Hematopoietic Stem Cell Transplantation (HSCT) Product Solution and Service3.5 Date of Enter into Hematopoietic Stem Cell Transplantation (HSCT) Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Historic Market Size by Type (2015-2020)4.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020)5.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)6.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in North America (2019-2020)6.3 North America Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)6.4 North America Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 7 Europe7.1 Europe Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)7.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in Europe (2019-2020)7.3 Europe Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)7.4 Europe Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 8 China8.1 China Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)8.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in China (2019-2020)8.3 China Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)8.4 China Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 9 Japan9.1 Japan Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)9.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in Japan (2019-2020)9.3 Japan Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)9.4 Japan Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)10.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)10.4 Southeast Asia Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 11 India11.1 India Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)11.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in India (2019-2020)11.3 India Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)11.4 India Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Hematopoietic Stem Cell Transplantation (HSCT) Market Size (2015-2020)12.2 Hematopoietic Stem Cell Transplantation (HSCT) Key Players in Central & South America (2019-2020)12.3 Central & South America Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type (2015-2020)12.4 Central & South America Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Regen Biopharma Inc13.1.1 Regen Biopharma Inc Company Details13.1.2 Regen Biopharma Inc Business Overview13.1.3 Regen Biopharma Inc Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.1.4 Regen Biopharma Inc Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020))13.1.5 Regen Biopharma Inc Recent Development13.2 China Cord Blood Corp13.2.1 China Cord Blood Corp Company Details13.2.2 China Cord Blood Corp Business Overview13.2.3 China Cord Blood Corp Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.2.4 China Cord Blood Corp Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.2.5 China Cord Blood Corp Recent Development13.3 CBR Systems Inc13.3.1 CBR Systems Inc Company Details13.3.2 CBR Systems Inc Business Overview13.3.3 CBR Systems Inc Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.3.4 CBR Systems Inc Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.3.5 CBR Systems Inc Recent Development13.4 Escape Therapeutics Inc13.4.1 Escape Therapeutics Inc Company Details13.4.2 Escape Therapeutics Inc Business Overview13.4.3 Escape Therapeutics Inc Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.4.4 Escape Therapeutics Inc Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.4.5 Escape Therapeutics Inc Recent Development13.5 Cryo-Save AG13.5.1 Cryo-Save AG Company Details13.5.2 Cryo-Save AG Business Overview13.5.3 Cryo-Save AG Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.5.4 Cryo-Save AG Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.5.5 Cryo-Save AG Recent Development13.6 Lonza Group Ltd13.6.1 Lonza Group Ltd Company Details13.6.2 Lonza Group Ltd Business Overview13.6.3 Lonza Group Ltd Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.6.4 Lonza Group Ltd Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.6.5 Lonza Group Ltd Recent Development13.7 Pluristem Therapeutics Inc13.7.1 Pluristem Therapeutics Inc Company Details13.7.2 Pluristem Therapeutics Inc Business Overview13.7.3 Pluristem Therapeutics Inc Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.7.4 Pluristem Therapeutics Inc Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.7.5 Pluristem Therapeutics Inc Recent Development13.8 ViaCord Inc13.8.1 ViaCord Inc Company Details13.8.2 ViaCord Inc Business Overview13.8.3 ViaCord Inc Hematopoietic Stem Cell Transplantation (HSCT) Introduction13.8.4 ViaCord Inc Revenue in Hematopoietic Stem Cell Transplantation (HSCT) Business (2015-2020)13.8.5 ViaCord Inc Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

More here:
Hematopoietic Stem Cell Transplantation (HSCT) Market is Thriving Worldwide with Top Companies like: China Cord Blood Corp, CBR Systems Inc, Escape...

Alyssa Mulvey in the Great North Children's Hospital at the RVI.

The total brought in by the man who walked 21 laps around Elizabethan walls earlier this month reached 2,000 earlier this week.

He was accompanied by Stewart Brown for the whole 26.2-mile marathon distance and family, friends and other supporters did some of the laps during the event in aid of wards in the Great North Children's Hospital (GNCH) at the RVI in Newcastle.

On his fund-raising page, Derek who lives in Highcliffe, Spittal specifically mentioned two local girls from Berwick (Alyssa Mulvey and Kelis Bloomfield) who are currently receiving treatment at the GNCH.

Alyssa has been poorly since birth and was diagnosed with A20 haploinsufficiency, a very rare auto-immune condition, when she was 10.

She has been on ward 3, a bone marrow transplant ward that deals with children who were born with zero immune systems or severe immune conditions. She had recovered well from a stem cell transplant last year, using stem cells donated by her dad Shane, but then contracted Covid-19.

Fortunately, Alyssa made an excellent recovery. However, a check-up weeks later revealed her blood pressure was extremely high and tests found that she had a serious kidney disease called thrombotic microangiopathy (TMA).

Although the condition was not caused by Covid-19, medics believe the virus ignited it in her system and that it had been dormant beforehand. She has now been at the GNCH for 21 consecutive weeks.

Kelis receives treatment on ward 2a. She has eosinophilic esophagitis (EoE), which is a chronic allergic inflammatory disease of the esophagus. She is allergic to things such as grass and pollen, which can cause respiratory failure.

Ward 2a specialises in respiratory and long-term ventilation, and diabetes.

Derek has previously supported the GNCH by doing the Great North Run half marathon his way of giving back to the team who saved the life of his daughter, Saskia, in 2018.

As the run was not held this year due to the coronavirus pandemic, he still wanted to do something in 2020 and so came up with the local challenge, which took place earlier this month before the extra local and national restrictions were announced.

He said: We set off just before 6am and after 8am, Deva (his wife) and Saskia joined us and walked the opposite way. Friends and supporters did some of the laps with us.

"We kept a brisk pace and when we had a break, we had a bacon roll and coffee courtesy of The Mule on Rouge.

"Many of the visitors on the day asked us why were doing the walk and a combination of visitors, friends and supporters saw a lot of people put money into the charity bucket that we had with us when we counted it later, the total in it was 255.

In the afternoon, Deva and Saskia completed half marathon distance and with six laps to go we were joined by the Plundering Pirates of the North East, dressed in costume, who raised money for their own charities. The last lap was done with Stewarts wife Amanda and their children, Mathew and Mia. Me and Stewart were pleased to complete the marathon distance in 10 hours.

Also thanks to all those who have donated online gf.me/u/yny5p2 its great that Ill be giving more than 1,000 to the two wards.

Alyssas mum Kirstie said that her daughter, 14, has infusions meds going in through a central line every day and has the dialysis procedure four to five times a week.

In relation to Dereks fund-raising, she said: He is amazing and we think he is an absolute superhero for helping to raise funds for and awareness of these wards.

The money will be vital for them because they are not as well known as others such as the cancer wards.

Other support for Alyssa and her family includes Kirsties best friend Julie Newton organising a raffle (1,000) and piping events on Thursday evenings at Mordington Avenue until last week (about 700 in total from the bucket donations each week).

Denise Lody from Facebook group Isolation Berwick upon Tweed and Surrounding Area set-up a GoFundMe page that raised 2,651.

Sean Ryan and Dave Smith of 2SPT raised 2,623.55 by running private physical training sessions through the lockdown period.

Further funds came from a beautiful cake raffled by Ashley McKnight and Berwick landscape postcards sold by Julie.

Kirstie said: The response has been unbelievable. Alyssa said to me why are they doing this for me, but I reminded her of how brave she is and told her how much people love her and they wanted to show just how much they care.

We were unable to speak in depth with Kelis mum Stacey, but she did send us a message that said: What Derek has done for these wards is absolutely amazing.

"Kelis has helped out by doing an online raffle, which raised 70 to the cause.

Originally posted here:
Marathon effort in aid of hospital wards - Berwick Advertiser

Medical skin care products are used for beautifying or to address some other skin care problems. The cosmetic industry is booming and skin care forms a very huge part of this industry. The aesthetic appearance is so important that people spend a lot on skin care products and treatment. People being more technologically aware of the various new skin care products trending in the market. In addition to the aesthetic application, the medical skin care products are also used to address issues such as acne, pimples or scars.

Medical Skin Care Products Market: Drivers and Restraints

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

To remain ahead of your competitors, request for a sample[emailprotected]

https://www.persistencemarketresearch.com/samples/18469

Medical Skin Care Products Market: Segmentation

On the basis of product type the medical skin care products market can be segmented as:

On the basis of application, the medical skin care products market can be segment as:

On the basis of distribution channel, the medical skin care products market can be segment as:

Medical Skin Care Products Market: Overview

Medical skin care products are used to address basic skin problems ranging from acne to scars. There are various advancements in the ingredients used to offer skin care products to the consumers. For instance, the use of hyaluronic acid and retinoids is the latest development in the industry. The anti-aging creams are at the forefront as the help treating issues such as wrinkles, scars, acne, and sun damage. Another, product in demand is the probiotic skincare which include lactobacillus and bifidobacterium.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/18469

Medical Skin Care Products Market: Region-wise Outlook

In terms of geography, medical skin care products market has been divided into five regions including North- America, Asia- Pacific, Middle-East & Africa, Latin America and Europe. North America dominated the global medical skin care products market as international players are acquiring domestic companies to make their hold strong in the U.S. LOral is accelerating its U.S. market by signing a definitive agreement with Valeant Pharmaceuticals International Inc. to acquire CeraVe, AcneFree and Ambi skin-care brands for US$ 1.3 billion. The acquisition is expected LOreal to get hold of the brands in the price-accessible segment. Asia Pacific is expected to be the fastest growing region owing to the increasing disposable income and rising awareness towards the skin care products.

Medical Skin Care Products Market: Key Market Participants

Some of the medical skin care products market participants are Avon Products Inc., Beiersdorf AG, Colgate-Palmolive Company, Kao Corporation, LOral S.A., Procter & Gamble, Shiseido Company, The Estee Lauder Companies Inc., Unilever PLC, Revlon, Clinique Laboratories, llc., Murad, LLC., SkinCeuticals, RMS Beauty, J.R. Watkins and 100% PURE.

You Can Request for TOC Here @https://www.persistencemarketresearch.com/toc/18469

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more here:
Europe to Show Consistency in the Medical Skin Care market from 2017 to 2025 - Crypto Daily

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, today announced that it has licensed intellectual property relating to its pioneering chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy to Chimeric Therapeutics Limited, an Australian biotechnology company.

The therapy is currently being used in a phase 1 clinical trial at City of Hope to treat glioblastoma (GBM), a type of brain tumor. The first patient in the trial was recently dosed; Behnam Badie, M.D., chief of City of Hopes Division of Neurosurgery and The Heritage Provider Network Professor in Gene Therapy, is leading this innovative, first-of-its-kind trial.

Chimeric has acquired the exclusive worldwide rights to develop and commercialize certain patents relating to City of Hopes CLTX-CAR T cells, as well as to further develop the therapy for other cancers.

City of Hope is excited to enter into this agreement with Chimeric as it supports our innovative research in CAR T cell therapy and our commitment to extend these therapies to more patients, particularly those with GBM and other solid tumors that are difficult to treat, said Christine Brown, Ph.D., The Heritage Provider Network Professor in Immunotherapy and deputy director of City of Hopes T Cell Therapeutics Research Laboratory. Chimeric shares our goal of providing effective CAR T cell therapies to more patients with current unmet medical needs.

Led by Brown and Michael Barish, Ph.D., chair of City of Hopes Department of Developmental and Stem Cell Biology, and Dongrui Wang, Ph.D., a recent graduate of City of Hopes Irell & Manella Graduate School of Biological Sciences, the team developed and tested the first CAR T cell therapy using CLTX, a component of scorpion venom, to direct T cells to target brain tumor cells. The research was published this past March in Science Translational Medicine.

Chimeric is excited to join City of Hope in its quest to find more effective cancer therapies. This is an exceedingly rare opportunity to acquire a promising technology in one of the most exciting areas of immuno-oncology today, said Paul Hopper, executive chairman of Chimeric. Furthermore, the CLTX-CAR T cell therapy has completed years of preclinical research and development, and recently enrolled its first patient in a phase 1 clinical trial for brain cancer.

CARs commonly incorporate a monoclonal antibody sequence in their targeting domain, enabling CAR T cells to recognize antigens and kill tumor cells. In contrast, the CLTX-CAR uses a synthetic 36-amino acid peptide sequence first isolated from death stalker scorpion venom and now engineered to serve as the CAR recognition domain.

In this recent study, City of Hope researchers used tumor cells in resection samples from a cohort of patients with GBM to compare CLTX binding with expression of antigens currently under investigation as CAR T cell targets. They found that CLTX bound to a greater proportion of patient tumors, and cells within these tumors.

CLTX binding included the GBM stem-like cells thought to seed tumor recurrence. Consistent with these observations, CLTX-CAR T cells recognized and killed broad populations of GBM cells while ignoring nontumor cells in the brain and other organs. The study team demonstrated that CLTX-directed CAR T cells are highly effective at selectively killing human GBM cells without off-tumor targeting and toxicity in cell-based assays and in animal models.

City of Hope, a recognized leader in CAR T cell therapies for GBM and other cancers, has treated more than 500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world it currently has 30 ongoing CAR T cell clinical trials, including CAR T cell trials for HER-2 positive breast cancer that has spread to the brain, and PSCA-positive bone metastatic prostate cancer. It was the first and only cancer center to treat GBM patients with CAR T cells targeting IL13R2, and the first to administer CAR T cell therapy locally in the brain, either by direct injection at the tumor site, through intraventricular infusion into the cerebrospinal fluid, or both. In late 2019, City of Hope opened a first-in-human clinical trial for patients with recurrent GBM, combining IL13R2-CAR T cells with checkpoint inhibitors nivolumab, an anti-PD1 antibody, and ipilimumab, blocking the CTLA-4 protein.

Both an academic medical center and a drug development powerhouse, City of Hope is known for creating the technology used in the development of human synthetic insulin and numerous breakthrough cancer drugs. Its unique research and development hybrid of the academic and commercial creates an infrastructure that enables City of Hope researchers to submit an average of 50 investigational new drug applications to the U.S. Food and Drug Administration each year. The institution currently holds more than 450 patent families.

"City of Hope is delighted to license this technology to Chimeric, said Sangeeta Bardhan Cook, Ph.D., City of Hope director of the Office of Technology Licensing. We are impressed with the ability of their executive team to push and bring therapies to market expeditiously. At City of Hope, our mission is to transform the future of health care. We believe Chimeric has the vision to offer innovative therapies to cancer patients.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

View post:
City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today announced that it has successfully completed the first dosing cohort in the Actimab-A and venetoclax combination, multi-center Phase 1 trial for patients with Relapsed or Refractory ("R/R") Acute Myeloid Leukemia (AML) age 18 and above. All patients from the first dosing cohort (0.50 uCi/kg of Actimab-A) completed treatment and cleared their initial safety evaluation, thus allowing the study to proceed to the second dose cohort of 1.0 uCi/kg Actimab-A added to venetoclax. In a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019, Actimab-A was shown to be synergistic with venetoclax in venetoclax resistant cell lines, by depleting MCL-1, a protein shown to mediate resistance to venetoclax. The ongoing Phase 1 study was planned to replicate this synergy in a clinical setting. Actinium plans to report study proof of concept results in 2021.

Venetoclax is a B-Cell Lymphoma 2 (BCL-2) inhibitor jointly developed and marketed by AbbVie and Genentech that is approved in combination with hypomethylating agents ("HMAs") for patients with AML. The use of venetoclax has become widespread in the treatment of fit and unfit patients with R/R AML following its inclusion in the recently expanded National Comprehensive Cancer Network ("NCCN") guidelines. Actinium's preclinical research has demonstrated that by adding Actimab-A to venetoclax, the targeted internalized radiation from Actimab-A can deliver potent AML cell killing, as well as effectively deplete MCL-1 levels. The overexpression of MCL-1, a member of the BCL-2 family which venetoclax does not inhibit, promotes resistance to venetoclax. Thus, Actimab-A reverses resistance to venetoclax and has independent anti-leukemic activity mediated by CD33 as well.

"We are pleased to confirm that the second combination trial in our CD33 program is advancing through the dose escalation study as planned. Despite approval in multiple blood cancers, including AML, most AML patients are not cured with venetoclax regimens and eventually relapse. Based on the preclinical data, synergy with venetoclax and Actimab-A should lead to higher remission rates in R/R AML," said Dr. Mark Berger, Actinium's Chief Medical Officer. "We continue to generate promising data from our broader combination program. For example, the Actimab-A combination trial with chemotherapy agent CLAG-M increased the complete response rate compared to CLAG-M alone in R/R AML patients by 60%. We expect to complete the proof of concept Actimab-A venetoclax combination trial in 2021."

This Phase 1 study is a multicenter, open label trial of Actimab-A added to venetoclax for patients with CD33 positive R/R AML. The study will continue to enroll patients that have been previously treated with venetoclax as well as venetoclax nave patients. Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program at the UCLA Medical Center is the Principal Investigator for this study. The trial is also active at the University of Louisville.

Sandesh Seth, Actinium's Chairman and Chief Executive Officer, said, "We continue to advance the CD33 program for fit and unfit R/R AML patients as there is still a significant unmet need despite multiple recently approved agents. These therapeutic agents are not curative and patients continue to experience low response rates and/or high relapse rates. Our CD33 program, which also includes the Actimab-A CLAG-M combination trial, is anchored in leveraging mechanistic synergies of Actimab-A with approved or novel therapeutic agents in order to improve patient outcomes. We look forward to multiple clinical trial updates by year-end from our three ongoing trials in R/R AML, including our Iomab-B SIERRA Phase 3 pivotal trial."

Rationale for Actimab-A Venetoclax Combination Trial

This Phase 1/2 trial is a multicenter, open label trial of Actimab-A (lintuzumab-Ac225) added to venetoclax for patients with CD33 positive relapsed/refractory (R/R) Acute Myeloid Leukemia. The Phase 1 portion of the study is designed to determine the maximum tolerated dose (MTD) of Actimab-A added to venetoclax for R/R AML. The Phase 2 portion of the trial will assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to six months after the start of the treatment without receiving other AML therapies. The trial will enroll R/R AML patients who have been treated with venetoclax as well as venetoclax-nave patients. At the 1.0 uCi/kg dose, Actimab-A is administered on Day 1 of each cycle for four cycles and venetoclax is taken on Days 1-21 of each cycle for up to 4 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery. Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program at the UCLA Medical Center is the Principal Investigator for this study.

More information on the clinical trial design is available at clinicaltrials.gov (NCT03867682).

About Actinium's CD33 Program (Actimab-A)

Antibody Radiation Conjugate (ARC) Actimab-A targets the CD33 antigen that is expressed on virtually all AML cells with the antibody lintuzumab which delivers potent alpha radiation via its Actinium-225 radioisotope payload. Blood cancers like AML are highly sensitive to radiation but cannot treated with the current standard of external beam delivery because the disease is too widespread throughout the body. The combination of targeted radiation with Actimab-A potentially allows for greater cancer cell death than a standalone chemotherapy regimen such as CLAG-M or venetoclax, which are frequently used in the treatment of fit and unfit patients with relapsed or refractory AML per National Comprehensive Cancer Network (NCCN) guidelines. Prior clinical results in over 100 patients treated with Actimab-A, including a Phase 1/2 trial of 58 patients, demonstrated a safety profile with minimal non-hematologic toxicities and an unmatched ability to deliver attenuated doses of radiation internally to CD33 expressing cancer cells. In the Phase 1/2 trial, Actimab-A as a single agent produced a 69% remission rate (CR, CRi, CRp) at high doses in patients with newly diagnosed AML but Actinium elected to pursue low dose combination trials for therapeutic development based on observed myelosuppression. In the Actimab-A CLAG-M Phase 1 combination trial, the second cohort with CLAG-M plus the 0.50 uCi/kg dose showed that 86% (6/7) of patients achieved complete remission (CR/CRi) after receiving the 0.50 uCi/kg dose of Actimab-A. This is a nearly 60% increase over the remission rate reported in a trial of seventy-four patients with relapsed or refractory AML who received CLAG-M alone. The company expects trial results, including the third dose cohort, in 2020. The Actimab-A Venetoclax Phase 1 trial continues to enroll patients in a maximum tolerated dose and expects to announce proof-of-concept results in 2021.

About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1/2 anti-HIV stem cell gene therapy with UC Davis and is expected to be studied with a CAR-T therapy in 2020. In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https://www.actiniumpharma.com/

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Contacts:

Investors:Clayton RobertsonActinium Pharmaceuticals, Inc.crobertson@actiniumpharma.com

Hans VitzthumLifeSci Advisors, LLCHans@LifeSciAdvisors.com(617) 535-7743

View original content to download multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-successfully-completes-first-dosing-cohort-in-the-phase-1-study-of-actimab-a-and-venetoclax-combination-therapy-in-relapsedrefractory-aml-patients-301136354.html

SOURCE Actinium Pharmaceuticals, Inc.

Company Codes: AMEX:ATNM

See the rest here:
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in...

Imagine if you could print yourself a new skin. Wrinkles and wounds begone with the flick of a switch. I appreciate that this sounds farfetched, but I have been looking into bioprinting and anti-aging applications are not so far off into the future.

So what is bioprinting?

Bioprinting is a type of 3D printing that uses actual cells and other biological materials as inks to fabricate 3D biological structures. Bioprinted materials have the potential to repair damaged organs, cells, and tissues in the human body (source). All sorts of cell types are being studied for bioprinting including stem cells, muscle cells, and endothelial cells. When printed, each layer of cells will cool and stick to one another (due to the collagen), creating a solid, stable structure.

Researchers have used bioprinting to introduce cells to help repair the heart after a heart attack as well as deposit cells into wounded skin.

A couple of years ago, researchers in Singapore mimicked human skin pigmentation using a 3-D bioprinter. he pigmented skin was constructed in vitro using three types of skin cells: keratinocytes, melanocytes and fibroblasts. Apparently, this was a breakthrough for the making biometic skin because while the skin itself isnt a problem, uniform pigmentation had been a real challenge.

A review of scientific literature, covering studies that mostly used collagen and hydrosol gels as the biometric ink, found that there had been a positive impact of natural bioinks in promoting wound healing. These have all been animal tests, but some researchers think that human wound healing with bioink will happen in the next 3-5 years.

A clue that we could see cosmetic skincare applications one day came when LOreal partnered with a 3-D bioprinting company to develop 3-D printed tissue for product evaluation and research (source).

Become a member to read this article in full

Your membership includes:

The rest is here:
Is Bioprinting the Future of Anti-aging Skincare? - Truth In Aging

Later that night, Fiona was searching her godfather's books on Amazon when she came across an unusual review.

"Dr Walker was my biological father and sperm donor," it read, and the commenter was trying to find out further information about him.

Fiona, curious, emailed the reviewer, Anne: She explained how she had letters and photographs, and she'd be willing to share them.

Through back-and-forth she'd discovered Dr Walker had assisted more than 100 families by using his own sperm.

By this point, Fiona was almost certain she was the result of this.

"When I fished out his letters, I found a drivers license of his that he had given me from when he was 16. And I showed it to my husband and said, 'Who does this look like?' and he just laughed, because it looks exactly like our youngest daughter," Fionasaid on SBS Insight.

"I went and had a chat to my mum and I said, 'Look, something's going on here and I'd like you to tell me the truth.'"

Fiona's mother told her they'd used a sperm donor. She said Dr Walker was her gynaecologist, and sperm donations usually come from medical students.

Fiona, then 53, asked her mother if Dr Walker was the donor, but her mother couldn't give her a straight answer.

Fiona and her mother. Image: Supplied.

She told Insight she was devastated.

"It made a lot ofsense, but at the same timeI was really angry that I'd been lied to. It was a bit of a rollercoaster, I'd be thinking it was prettycool one moment and then prettyhorrible the next moment. It's been like that eversince," she said.

Go here to see the original:
'Who does this look like?' Fiona was scrolling online when she discovered a family secret. - Mamamia

Fort Collins, Colorado Reports Globe recently added the Stem Cell Therapy Market Research Report that provides a thorough investigation of the market scenario of the market size, share, demand, growth, trends, and forecast from 2020-2027. The report covers the impact analysis of the COVID-19 pandemic. COVID-19 pandemic has affected the export-import, demands, and trends of the industry and is expected to have some economic impact on the market. The report provides a comprehensive analysis of the impact of the pandemic on the overall industry and offers insights into a post-COVID-19 market scenario.

The report primarily mentions definitions, classifications, applications, and market overview of the Stem Cell Therapy industry. It also covers product portfolios, manufacturing processes, cost analysis, structures, and gross margin of the industry. It also provides a comprehensive analysis of the key competitors and their regional spread and market size.

Global Stem Cell TherapyMarketwas valued at 117.66 million in 2019 and is projected to reach USD255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=33553

Competitive Analysis:

The report provides a comprehensive analysis of the companies operating in the Stem Cell Therapy market, along with their overview, business plans, strengths, and weaknesses to provide a substantial analysis of the growth through the forecast period. The evaluation provides a competitive edge and understanding of their market position and strategies undertaken by them to gain a substantial market size in the global market.

Key features of the Report:

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

Additionally, the report is furnished by the advanced analytical data from SWOT analysis, Porters Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis. The report also provides a detailed analysis of the mergers, consolidations, acquisitions, partnerships, and government deals. Along with this, an in-depth analysis of current and emerging trends, opportunities, threats, limitations, entry-level barriers, restraints and drivers, and estimated market growth throughout the forecast period are offered in the report.

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

The report provides additional analysis about the key geographical segments of the Stem Cell Therapy Market and provides analysis about their current and previous share. Current and emerging trends, challenges, opportunities, and other influencing factors are presented in the report.

Regional analysis includes an in-depth study of the key geographical regions to gain a better understanding of the market and provide an accurate analysis. The regional analysis coversNorth America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Objectives of the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read the original here:
Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - The Daily Chronicle

InYourArea Community

Blood Cancer charity DKMS thanks the public in the North West for going against the grain and registering as blood stem donors.

DKMS is thanking people in the North West this Blood Cancer Awareness Month (September, 1-30 2020) for registering as blood stem cell donors during lockdown. The North West has provided the fourth highest number of registrations during lockdown. However there is still an urgent need for registrations to help meet the demand and reverse the shocking decline in new registrations in recent times and potentially help save a life.

Every 20 minutes someone in the UK is diagnosed with a blood cancer and it is the third most common cause of cancer death in the UK. A stem cell transplant can be the last hope of survival for patients and during the coronavirus outbreak, it is even more important to offer hope to people with devastating blood cancers and blood disorders, whose lives have also been harmed by the pandemic.

A blood stem cell donation from a genetically similar person can offer a second chance at life for those in need. Only 1 in 3 people with blood cancer (and in need of a transplant) will find a matching blood stem cell donor within their own family which means that 2 in 3 need to look outside of this and rely on an altruistic stranger to help give them more time with their family.

Many people are unaware of how they can donate blood stem cells. Around 90% of all donations are made through a method called peripheral blood stem cell. While just 10% of cases, donations are made through bone marrow collection, which contrary to what people think, is not extracted from the spine but from the pelvic bone.

DKMS Donor Recruitment Manager, Louise Clague, 50, from Cheshire joined the fight against blood cancer and is on a mission to register as many potential blood stem cell donors as possible after her husband, Andy Clague, died in December 2017, aged 46, following a two-year battle with non-Hodgkins lymphoma.

Louise said: Raising awareness of blood cancer and how people can become potential blood stem cell donors has partly been my way of dealing with grief and having something where you feel like youre making a difference. I have a son and a daughter who are now 14 and 17 who have lost a dad. You dont want other people to go through the same ordeal.

"We were referred to as the fit family and we have no history of the condition in the family but it happened to us. So that is part of the message, it could be you and if it happened to you and your family, would you give your blood stem cells? I think a lot of people would and I think people havent signed up yet because theyve never come across the condition."

Taking the first steps to register as a potential blood stem cell donor can be done within a few minutes from the comfort of your own home. If you are aged between 17-55 and in general good health you can sign up for a home swab kit on the DKMS website. Your swabs can then be returned with the enclosed pre-paid envelope to DKMS in order to ensure that your details are added to the UKs aligned stem cell registry.

Read the original here:
Blood Cancer charity thanks the North West for registering as donors - In Your Area

A new research report published by Fior Markets with the titleCord Blood Banking Market by Type of Bank (Public, Private), Services (Processing, Storage), Application (Cancer, Blood Disorders, Immuno-deficiency Disorders, Metabolic Disorders, Bone Marrow Failure Syndrome), End-User (Hospitals, Research Institutes, Specialty Clinics), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027.

Theglobal cord blood banking marketis expected to grow from USD 16.88 billion in 2019 to USD 25.90 billion by 2027, at a CAGR of 5.5% during the forecast period 2020-2027. The North America region dominates the market and holds the largest share in the year 2019. This growth is ascertained to the increasing investment in public banking, increasing awareness of long-term benefits, and reduction in storage costs. The Asia-Pacific region is projected to witness significant growth, owing to the increasing awareness regarding the advantages of preservation of cord blood cells in developing economies like China and India.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/418891/request-sample

Some of the notable players in the market are CBR Systems, Singapore Cord Blood Bank, Cryo-Save, ViaCord LLC, Global Cord Blood Corporation, Jeevan Stem Cell Foundation, LifeCell, Cordlife, Americord, and FamiCord. In April 2019, FamiCord announced a future business corporation agreement with CelluGen Biotech. This agreement will help in generating beneficial synergies with both the companies in the field of development of new stem cell-based drugs and family-based stem cell banking.

The type of bank segment is classified into public and private. The public segment holds the largest market share, owing to the various funding initiatives, and various government initiatives for encouraging expectant mothers to donate cord blood cells in public banks. The private cord blood banks are expected to witness significant growth, owing to the growing awareness among expectant parents and high demand to safeguard the health of family members. The service segment includes processing and storage. The storage segment holds the largest market share, due to the increasing number of expectant parents utilizing the preservation of newborn cord blood cells. The processing segment is expected to witness significant growth due to various technological advancements in cord blood processing methods. Based on application, the market is classified into cancer, blood disorders, immuno-deficiency disorders, metabolic disorders, and bone marrow failure syndrome. Blood disorders segment holds the largest market share. This growth is attributed to the increasing application of cord blood cells in the treatment of blood disorders and the increasing prevalence of beta-thalassemia. Immuno-deficiency disorders are expected to witness significant growth, owing to the rapid and reliable recovery of immune function, low viral transmission rate, and low risk of graft versus host diseases. The end-user segment is distributed into hospitals, research institutes, and specialty clinics. The research institute segment holds the largest market share, owing to the growth in the number of clinical trials for exploring new diseases and growing pervasiveness of genetic disorders. Hospitals segment is expected to witness significant growth, owing to the advancement in cord blood banking, increasing prevalence of genetic diseases.

The factors influencing the market growth are rising awareness about therapeutic applications of cord blood, government initiatives and funding in developed economies, increasing prevalence of life-threatening genetic diseases, and growing clinical trials in regenerative medicines. Lack of uniformity in regulatory policies, large out-of-pocket expenditure, and low acceptance rate in developing countries are the factors hampering the market growth. Increasing research concerns about cord blood application for the treatment of genetic and idiopathic disorders will provide market growth opportunities.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/cord-blood-banking-market-by-type-of-bank-418891.html

About the report:The globalCord Blood Bankingmarket is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Follow this link:
Global Cord Blood Banking Market is Anticipate to Reach at a CAGR of 5.5% during the forecast period - PharmiWeb.com

A surface view of the organ of hearing (cochlea) from a mouse, using confocal microscopy. The sensory cells are named hair cells because of their apical projections (stereocilia) which move from stimulation by sound.

University of Maryland School of Medicine

Researchers at the University of Maryland School of Medicine (UMSOM) have conducted a study that has determined the role that a critical protein plays in the development of hair cells. These hair cells are vital for hearing. Some of these cells amplify sounds that come into the ear, and others transform sound waves into electrical signals that travel to the brain. Ronna Hertzano, MD, PhD, associate professor in the Department of Otorhinolaryngology Head and Neck Surgery at UMSOM and Maggie Matern, PhD, a postdoctoral fellow at Stanford University, demonstrated that the protein, called GFI1, may be critical for determining whether an embryonic hair cell matures into a functional adult hair cell or becomes a different cell that functions more like a nerve cell or neuron.

The study was published in the journalDevelopment, and was conducted by physician-scientists and researchers at the UMSOM Department of Otorhinolaryngology Head and Neck Surgery and the UMSOM Institute for Genome Sciences (IGS), in collaboration with researchers at the Sackler School of Medicine at Tel Aviv University in Israel.

Hearing relies on the proper functioning of specialized cells within the inner ear called hair cells. When the hair cells do not develop properly or are damaged by environmental stresses like loud noise, it results in a loss of hearing function.

In the United States, the prevalence of hearing loss doubles with every 10-year increase in age, affecting about half of all adults in their 70s and about 80 percent of those who are over age 85. Researchers have been focusing on describing the developmental steps that lead to a functional hair cell, in order to potentially generate new hair cells when old ones are damaged.

To conduct her latest study, Hertzano and her team utilized cutting-edge methods to study gene expression in the hair cells of genetically modified newborn mice that did not produce GFI1. They demonstrated that, in the absence of this vital protein, embryonic hair cells failed to progress in their development to become fully functional adult cells. In fact, the genes expressed by these cells indicated that they were likely to develop into neuron-like cells.

"Our findings explain why GFI1 is critical to enable embryonic cells to progress into functioning adult hair cells," said Hertzano. "These data also explain the importance of GFI1 in experimental protocols to regenerate hair cells from stem cells. These regenerative methods have the potential of being used for patients who have experienced hearing loss due to age or environmental factors like exposure to loud noise."

Hertzano first became interested in GFI1 while completing her MD, PhD at Tel Aviv University. As part of her dissertation, she discovered that the hearing loss resulting from mutations in another protein called POU4F3 appeared to largely result from a loss of GFI1 in the hair cells. Since then, she has been conducting studies to discover the role of GFI1 and other proteins in hearing. Other research groups in the field are now testing these proteins to determine whether they can be used as a "cocktail" to regenerate lost hair cells and restore hearing.

"Hearing research has been going through a Renaissance period, not only from advances in genomics and methodology, but also thanks to its uniquely collaborative nature among researchers," said Hertzano.

The new study was funded by the National Institute on Deafness and Other Communication Disorders (NIDCD) which is part of the National Institutes of Health (NIH). It was also funded by the Binational Scientific Foundation (BSF).

"This is an exciting new finding that underscores the importance of basic research to lay the foundation for future clinical innovations," said E. Albert Reece, MD, PhD, MBA, executive vice president for medical affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and dean, University of Maryland School of Medicine. "Identifying the complex pathways that lead to normal hearing could prove to be the key for reversing hearing loss in millions of Americans."

- This press release was originally published on theUniversity of Maryland School of Medicine website

Originally posted here:
Researchers ID Role of Protein in Development of New Hearing Hair Cells - labmanager.com

Sciences most powerful ingredients are better together.

Every skin-care enthusiast has heard of retinol, the dermatological gold standard in anti-aging and vitamin A derivative that lessens the appearance of fine lines and wrinkles, promotes collagen production, minimizes breakouts, and resurfaces your skin. But the famed ingredient is also known for some of its less desirable side effectsnamely, irritation, redness, flaking, and photosensitivity, which can make it intolerable for sensitive skin types and unsafe for use in pregnant and nursing women.

Even as most dermatologists laud retinol for its extensive benefits, holistic aestheticians remain wary of the actives corrosive effects on the skin barrier. Because the skin barrier is key for retaining moisture and protecting the dermis from external irritants, aggressors, pollutants, and more, compromising it can sensitize skin, making it more susceptible to inflammation and irritation.

Growth factors have piqued our interest for being a sensitive-skin-friendly alternative to retinol, as these pro-healing proteins are safe for more continued use and are non-corrosive to the stratum corneumthe outermost layer of the epidermisand are gentle enough for sensitive skin types. But if youre not quite ready to let go of your retinol, it turns out that they can be used together to enhance the potency of your anti-aging regimen, even buffering the skin from some of retinols less desirable side effects.

Keep reading to get schooled on the use of growth factors in skin care according to dermatologists, and some guidance on whether the controversial ingredient could be right for you to try next.

Advertisement

As we grow older, our skins natural production of collagen decreases (starting around age 25), the elastin fibers begin to stiffen, and our skin produces lower quantities of growth factors, resulting in various signs of aging, like fine lines, crepiness, thinness, and sagging. This is where adding a topical growth factor into your routine can help. Says Lily Talakoub, MD, dermatologist and owner of dermtodoor.com, A growth factor is a large protein derived from human cells that targets the crucial turnover of cells, [promoting the increase] of [structural proteins] such as collagen and elastin.

Although they were first discovered in the 1950sand the scientists who did it were awarded the Nobel Prize for their research in 1986there was still some confusion as to how growth factors worked and their efficacy. But in the last few years, there has been a flurry of new anti-aging products that use growth factors like EGF (epidermal growth factor).

As Dr. Talakoub explains, growth factors stimulate the regeneration of cells that fight various signs of aging by prompting the cells to produce the structural components of the skin that are responsible for elasticity, firmness, and bounce. Specifically, ultra-healing EGF binds to the EGF receptor in the cell, aiding with cell proliferation, survival, and promoting DNA synthesis. By fortifying the presence of the structural tissues in the skin matrix, research shows that we can expect fewer fine lines and wrinkles over time. Think of growth factors as the key that unlocks and activates the cell to produce collagen and elastinboth of which give us that youthful lookand also help promote cell turnover and fight against inflammation.

As board-certified dermatologist Dr. Hadley King points out, growth factors like EGF can also be used to increase skin thickness and to improve tone and texture, particularly for sensitive skin types. If your skin is too sensitive to tolerate retinoids, then growth factors can be a substitute to stimulate collagen, even tone, and decrease roughness with much less irritation.

Dr. King explains that these proteins are almost universally tolerable, likely due to their natural presence in the body, and through inducing the bodys own natural mechanisms for repair, which in turn promotes skin healing. When they bind to receptors on cell surfaces, King continues, they send commands to repair, rejuvenate, and replicate. This makes them an excellent option for skin concerns ranging from inflammation and acne to fading scarring and post-inflammatory hyperpigmentation.

Thanks to the Kardashians, youve undoubtedly heard of the trendy vampire facial, which uses your bodys own PRPplatelet-rich plasma that is derived from your own bloodto treat acne scars and smooth skin texture. This makes them a fantastic addition to your post-laser or post-microneedling treatment at the dermatologist. Adding a growth factor serum like PRP can also enhance the efficacy of the treatment, as well as reduce healing time.

While a PRP serum created in a centrifuge from your own blood is the ultimate way to go for an in-office encounter with growth factors, you can also follow up at home with a growth-factor-based serum to maximize your treatments effects. Just be sure to perform a patch test before applying it to the area that was treated, as that skin might still be extra sensitive and prone to inflammation.

Advertisement

One of the most important things to consider when selecting a growth factor comes down to the source. When we think of epidermal growth factor (EGF), there are two common methods of sourcing: bio (i.e., human- or animal-derived) and phyto (i.e., plant-derived). The general consensus within the scientific community seems to be that human-derived growth factors, especially PRP, are the most effective. Says Dr. Talakoub, Plant-based growth factors do not stimulate the growth of in vivo cells [in] the same [way] as ones derived from human cells.

However, not everyone is comfortable using a biological source for their skin-care products, even if they might deliver superior results. In products like the wildly popular growth-factor-based serums from SkinMedica and NeoCutis, the initial cell samples were obtained from neonatal fetal foreskin and fetal fibroblast cells, respectively, before being grown in the lab for use in their products. Depending on your ethical and political views, this might be an issue to consider before you try using these types of formulas.

And while these holy grail serums do use human stem cells, keep in mind that there are no body partswe repeat, absolutely no penises!in these serums, despite what Cate Blanchett says.

If youd rather bypass the ethical controversy of a human- or animal-derived growth factor altogether, rest assured that there are plant-based options. There are some engineered options that have been well tested and shown to be effective, says Dr. King, noting that the brands BIOEFFECT and DNA Renewal have both exhibited promising results related to skin repair, rejuvenation, and enhancement via a humanlike epidermal growth factor made in bio-engineered barley seeds.

Dr. Bjrn rvar, co-founder and chief scientific officer of BIOEFFECT, the makers of the worlds first bio-engineered, plant-based EGF, strongly believes that phyto-EGF is the new frontier in terms of tolerability, efficacy, and even safety. EGF has previously been grown in bacteria, which poses a risk of endotoxins, or extracted from human or animal cells, which presents ethical, moral, and legal issues as well as safety issues.

There are also upsides to selecting a phyto-sourced, synthetic EGF that go beyond ethics and speak to precision and measurable outcomes. The advantage to plant-derived growth factors is that there is a more defined concentration of known synthetic growth factors, and so it is theoretically easier to measure and predict outcomes, says dermatologist Dr. Mamina Turegano. And now with studies pointing to phyto sources of growth factor improving epidermal thicknesswhich thins as we agethese phyto-sourced options could be the new frontier in terms of bypassing the controversy altogether.

Because these two anti-aging actives work differently, with retinol promoting the turnover of keratinocytes (the primary type of cell in your epidermis) and growth factors targeting the formation of cells that produce collagen and elastin and strengthening your skin barrier, EGF and retinol can be used together to maximize your anti-aging skin-care routine.

So what happens when you use a growth factor along with a retinol product? Most growth factors are extremely large proteins [which] have a very difficult time penetrating the outer lipid bilayer of the skin, says Talakoub. Using a retinoid in combination with a growth factor allows [it] to penetrate the outer layers of the skin. She suggests using a vitamin C product during the daytime, and then layering your EGF with your retinol at night to see the best results.

If you do choose to use an EGF serum in conjunction with your favorite retinol, rvar recommends a particular process. We recommend always applying the EGF serum first, on clean skin, and allowing 510 minutes before applying anything else on top [to] give it time to activate the skin cells and do its magic, he notes. As he explains, EGF will help to boost hydration and counter the thinning of the skins outer layer that can occur with retinol. Their synergistic effects are the perfect complement to each other and will help make your anti-aging skin-care routine even more effective.

Advertisement

EGF Serum$160Buy

Regeneration Serum$192Buy

Copper Peptide & EGF Ampoules$125Buy

Lumire Illuminating Eye Cream$97Buy

Creme PlacentaPrice Upon RequestBuy

TNS Essential Serum$281Buy

Tensage Intensive Serum 40$136Buy

Rejuvenating Rich Moisture Cream with MHCsc Technology$120Buy

Visit link:
The Anti-aging Benefits of Using Growth Factors Plus Retinol - Coveteur

The medical skin care products is primarily driven by the need of natural based active ingredients products which are now trending in the market. Consumers demand medical skin care products which favor health and environment. Moreover, the consumers are updated with the trends so that various companies end up providing such products to satisfy the customers. For instance, a single product face mask has thousands of different variants. This offers consumers different options to select the product depending on the skin type. Moreover, the market players catering to the medical skin care products are offering products with advanced technologies. For instance, Santinov launched the CICABEL mask using stem cell material based on advanced technologies. The stem cells used in the skin care product helps to to protect and activate the cells and promote the proliferation of skin epidermal cells and the anagenesis of skin fibrosis.

Read more:
The Medical Skin Care Products market to Witness an Impulse between 2017 and 2025 - Industry Today

If you regularly read my beauty content (thanks and Hi mum!), you'll know that I'm a huge fan of celebrity skincare fave, iS Clinical. Their formulas are revered for combining highly active ingredients and plant-derived extracts with modern science. They're all are fragrance and paraben-free and directly tackle all major skin concerns dry, dull skin, anti-ageing, pigmentation, uneven skin tone and texture.

About three or so months ago, they finally landed an Australian stockist and I was able to get my hands on their Reparative Moisture Emulsion and Pro-Heal Serum. To say I was impressed with the results was an understatement, so I decided it was time to bench my go-to cleanser and give their cult-classic Cream Cleanser a whirl.

When it comes to ingredients, iS Clinical only use high-grade, dermatologist-recommended ingredients like plant-derived acids, vitamins A to E, stem cells and ceramides, so you know that you're going to get good results. But this, this cleanser surpassed my expectations and is perfect if, like me, you're lazy and CBF washing your face too regularly. (Naughty beauty writer, I know).

The Cream Cleanser combines bio-nutrients, antioxidants, and restorative ingredients that work to thoroughly cleanse the surface and pores of the skin while soothing the look and feel of any dry patches. One of my favourite parts about this cleanser is that post-cleanse, your skin is left feeling refreshed, hydrated and clean, rather than tight and dried out. My other favourite part (and here's where my inner lazy girl fell in love) is that you don't even have to wash it off, you can simply wipe it off with a muslin cloth and voila, you're done.

I've been using this cream cleanser for about a month now and I've already noticed a difference in my skin. And I'm not alone, Chrissy Teigen, Rosie Huntington-Whiteley, January Jones and Zoey Deutch are all huge fans, too!

Scroll to shop iS Clinical's Cream Cleanser.

The rest is here:
I Used to Hate Washing My Face But Now I'm Reaching for This Cult-Cleanser Constantly - POPSUGAR Beauty Austrailia

Anti-Ageing Drugs Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Anti-Ageing Drugs market is a compilation of the market of Anti-Ageing Drugs broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Anti-Ageing Drugs industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Anti-Ageing Drugs industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Anti-Ageing Drugs Market report @ https://hongchunresearch.com/request-a-sample/61916

The following manufacturers are covered:Nu SkinBIOTIMEElysium HealthLa Roche-PosayDermaFix

Access this report Anti-Ageing Drugs Market @ https://hongchunresearch.com/report/worldwide-anti-ageing-drugs-market-2019-61916

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeHormonal TherapyAntioxidantsEnzymesStem CellsOthers

Segment by ApplicationSkinHairOthers

For a global outreach, the Anti-Ageing Drugs study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Anti-Ageing Drugs Market @ https://hongchunresearch.com/check-discount/61916

Major Point of TOC:

Chapter One: Anti-Ageing Drugs Market Overview

Chapter Two: Global Anti-Ageing Drugs Market Competition by Manufacturers

Chapter Three: Global Anti-Ageing Drugs Production Market Share by Regions

Chapter Four: Global Anti-Ageing Drugs Consumption by Regions

Chapter Five: Global Anti-Ageing Drugs Production, Revenue, Price Trend by Type

Chapter Six: Global Anti-Ageing Drugs Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Anti-Ageing Drugs Business

Chapter Eight: Anti-Ageing Drugs Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Anti-Ageing Drugs Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Follow this link:
Impact Of Covid-19 on Anti-Ageing Drugs Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily Chronicle